AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
68.99
-0.29 (-0.42%)
May 6, 2026, 2:15 PM EDT - Market open
AnaptysBio Employees
AnaptysBio had 104 employees as of December 31, 2025. The number of employees decreased by 32 or -23.53% compared to the previous year.
Employees
104
Change (1Y)
-32
Growth (1Y)
-23.53%
Revenue / Employee
$2,255,798
Profits / Employee
-$127,231
Market Cap
1.98B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 104 | -32 | -23.53% | 104 | 0 |
| Dec 31, 2024 | 136 | 19 | 16.24% | 136 | 0 |
| Dec 31, 2023 | 117 | 21 | 21.88% | 117 | 0 |
| Dec 31, 2022 | 96 | -6 | -5.88% | 96 | 0 |
| Dec 31, 2021 | 102 | 8 | 8.51% | 102 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 767 |
| Ocular Therapeutix | 325 |
| Zymeworks | 264 |
| Capricor Therapeutics | 231 |
| Stoke Therapeutics | 170 |
| Pharvaris | 129 |
| Aurinia Pharmaceuticals | 128 |
| Taysha Gene Therapies | 99 |
ANAB News
- 1 day ago - Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - GlobeNewsWire
- 7 days ago - Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - PRNewsWire
- 11 days ago - Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim - GlobeNewsWire
- 16 days ago - Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations - GlobeNewsWire
- 5 weeks ago - Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics - GlobeNewsWire
- 5 weeks ago - Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update - GlobeNewsWire
- 5 weeks ago - First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement - GlobeNewsWire
- 2 months ago - AnaptysBio Transcript: Leerink Global Healthcare Conference 2026 - Transcripts